In short
A new clinical trial is underway to assess the efficacy of two treatments, 2LEBV® and 2LXFS®, in reducing fatigue and other symptoms associated with Epstein-Barr Virus (EBV) infection. This randomized, placebo-controlled, double-blind study aims to provide valuable insights into managing the debilitating effects of EBV, particularly focusing on fatigue severity and other related symptoms. The trial will involve patients aged 12 and older who have been experiencing significant fatigue for at least one month, along with other EBV-related symptoms.
At a glance
- Study Type
- Randomized, placebo-controlled, double-blind clinical trial
- Treatments Evaluated
- 2LEBV® and 2LXFS®/2LEBV®
- Primary Objective
- Evaluate efficacy in reducing fatigue severity in EBV patients
- Secondary Objectives
- Assess impact on other EBV-related symptoms, lymphocyte typing, and antibody levels
- Participant Age
- 12 years and older
- Key Inclusion Criteria
- Significant fatigue for 1+ month, 2+ other EBV symptoms, positive EBV serology
- Primary Endpoint
- General fatigue scale of MFI-20 questionnaire at 6 months
- Treatment Duration
- 6 months, with follow-ups at 3 and 12 months
- Safety Monitoring
- Occurrence of Adverse Events (AEs) and Severe Adverse Events (SAEs)
What is SPECIFIC NUCLEIC ACID SNA-XFSA?
SPECIFIC NUCLEIC ACID SNA-XFSA is a medical substance being studied as a potential treatment for Epstein-Barr Virus (EBV) infection. It is also known as "SNA-XFSa" or "SPECIFIC NUCLEIC ACID - CHRONIC FATIGUE SYNDROME TOXOPLASMA". This substance is classified as a nucleic acid, which means it's related to the genetic material found in our cells.
SNA-XFSA is part of a medication called 2LXFS, which contains several other active substances, including other specific nucleic acids, proteins, and immune system modulators. This combination of substances suggests that 2LXFS is designed to interact with the body's immune system to potentially combat the Epstein-Barr Virus.
Target Condition: Epstein-Barr Virus Infection
The Epstein-Barr Virus (EBV) is a common virus that can cause various symptoms, including:
- Fatigue
- Fever
- Sore throat
- Swollen lymph nodes
- Enlarged spleen
In some cases, EBV infection can lead to a condition called chronic fatigue syndrome, which is characterized by long-lasting exhaustion that doesn't improve with rest.
Clinical Trial Overview
A clinical trial is currently being conducted to evaluate the effectiveness of 2LXFS (which contains SNA-XFSA) in treating fatigue associated with EBV infection. This trial is:
- Randomized: Participants are randomly assigned to different treatment groups
- Placebo-controlled: Some participants receive a placebo (inactive substance) for comparison
- Double-blind: Neither the participants nor the researchers know who is receiving the actual treatment or placebo
The main goal of this study is to compare the effectiveness of 2LXFS in reducing fatigue severity compared to a placebo.
Potential Benefits
While the effectiveness of SNA-XFSA is still being studied, the clinical trial aims to determine if it can help with:
- Reducing fatigue severity
- Improving other symptoms related to EBV infection
- Positively affecting the immune system, as measured by changes in lymphocyte (a type of white blood cell) levels
How is it Administered?
2LXFS, which contains SNA-XFSA, is administered in the form of pillules. Pillules are very small pills, often used in homeopathic treatments. The medication is taken through oromucosal use, which means it's applied to the mucous membrane of the mouth.
Who is Eligible for the Treatment?
The clinical trial has specific criteria for who can participate. Generally, eligible participants are:
- 12 years of age or older
- Experiencing significant fatigue for at least one month
- Having at least two other symptoms related to EBV infection
- Testing positive for EBV antibodies
However, there are also several conditions that would exclude someone from participating, such as recent use of certain medications or having specific health conditions.
Safety Considerations
As with any medical treatment, safety is a crucial concern. The clinical trial is monitoring for any adverse events (side effects) that may occur during the treatment. It's important to note that this medication is still being studied, and its full safety profile is not yet established.
Patients with certain conditions, such as galactose intolerance or glucose-galactose malabsorption syndrome, should not take this medication.